# SGCA

## Overview
The SGCA gene encodes the alpha-sarcoglycan protein, a transmembrane protein that is a critical component of the sarcoglycan complex within the dystrophin-glycoprotein complex (DGC) in muscle cells. This protein plays a pivotal role in maintaining the structural integrity of muscle fibers by linking the cytoskeleton to the extracellular matrix, thereby ensuring proper muscle function and stability during contraction and relaxation cycles (Vainzof2021Sarcoglycanopathies:; Ozawa2005Molecular). Alpha-sarcoglycan is involved in signaling pathways, such as those mediated by fibroblast growth factor receptor 1 (FGFR1), which are essential for muscle cell proliferation and differentiation (Cassano2011Alpha). Mutations in the SGCA gene are associated with limb-girdle muscular dystrophy type 2D (LGMD2D), a condition characterized by progressive muscle weakness and potential complications such as cardiomyopathy (Chung2023Novel; AlonsoPérez2020New).

## Structure
The human SGCA gene encodes the alpha-sarcoglycan protein, which is a component of the sarcoglycan complex, crucial for muscle fiber integrity. The primary structure of alpha-sarcoglycan consists of 387 amino acids, with a signal sequence of 23 amino acids at its N-terminus. The core protein, excluding the signal sequence, has a calculated molecular mass of 40.4 kDa, but the native glycosylated form is approximately 50 kDa as determined by SDS-PAGE (Ozawa2005Molecular).

The protein features a membrane-spanning domain of 21 amino acids, separating its extracellular and intracellular domains, which comprise 267 and 76 amino acids, respectively (Ozawa2005Molecular). Alpha-sarcoglycan contains a cadherin-like domain and calcium-binding pockets near the signal sequence, which are thought to facilitate protein-protein interactions (Ozawa2005Molecular).

Post-translational modifications include glycosylation at two asparagine residues and phosphorylation at a serine residue near the C-terminus (Mickelson2021Sarcoglycan). The quaternary structure involves its assembly with other sarcoglycans, forming a complex that interacts with the dystroglycan complex on the cell membrane and binds strongly to sarcospan, serving as a scaffold for anchoring on the cell membrane (Ozawa2005Molecular).

## Function
The SGCA gene encodes the alpha-sarcoglycan protein, a crucial component of the sarcoglycan subcomplex within the dystrophin-glycoprotein complex (DGC) in muscle cells. This complex plays a vital role in maintaining the integrity of the muscle cell membrane, particularly during contraction and relaxation cycles, by linking the cytoskeleton to the extracellular matrix (Vainzof2021Sarcoglycanopathies:; Ozawa2005Molecular). In healthy cells, alpha-sarcoglycan is involved in fibroblast growth factor (FGF) signaling, specifically through its interaction with the FGF receptor 1 (FGFR1). This interaction is essential for the proliferation and early differentiation of myogenic progenitor cells (MPCs), as it stabilizes the FGFR1 complex on the cell membrane, promoting cell proliferation in response to basic FGF (bFGF) (Cassano2011Alpha).

Alpha-sarcoglycan also contributes to the structural stability of the DGC, preventing muscle damage by ensuring the proper function of the sarcoglycan complex. Its absence can lead to impaired muscle regeneration and increased susceptibility to muscular dystrophies, as the sarcoglycan complex is crucial for muscle cell membrane stability and function (Vainzof2021Sarcoglycanopathies:; Ozawa2005Molecular).

## Clinical Significance
Mutations in the SGCA gene, which encodes the alpha-sarcoglycan protein, are primarily associated with limb-girdle muscular dystrophy type 2D (LGMD2D). This condition is characterized by progressive muscle weakness, particularly affecting the proximal muscles of the shoulder and pelvic girdles. Patients often experience elevated serum creatine kinase levels, indicating muscle damage (Chung2023Novel; Xie2019Clinical). 

The most common mutation in SGCA is the c.229C>T (p.Arg77Cys) variant, which leads to significantly reduced protein expression and is linked to early onset and rapid disease progression (AlonsoPérez2020New). Other mutations, such as c.983+5G>C and c.257_258insTGGCT, have also been identified and are considered pathogenic, contributing to the clinical variability observed in LGMD2D (Chung2023Novel).

In addition to muscle weakness, some patients may develop cardiomyopathy and respiratory deficiencies, although these complications are less frequently reported (Trabelsi2008Revised; AlonsoPérez2020New). The severity of the disease is inversely proportional to the amount of functional alpha-sarcoglycan protein present in muscle cells, with complete absence leading to more severe phenotypes (Chung2023Novel).

## Interactions
Alpha-sarcoglycan (SGCA) is a component of the sarcoglycan complex, which is part of the larger dystrophin-glycoprotein complex (DGC) in muscle cells. This complex is crucial for linking the cytoskeleton to the extracellular matrix, thereby maintaining muscle integrity and function. SGCA interacts with other sarcoglycans, including beta, gamma, and delta sarcoglycans, to form a stable complex that is essential for muscle cell stability (Kobuke2008A).

SGCA also interacts with fibroblast growth factor receptor 1 (FGFR1), forming a complex that is critical for the proper localization and function of FGFR1 on the cell membrane. This interaction is necessary for fibroblast growth factor (FGF)-dependent signaling pathways, which are important for the proliferation of myogenic progenitor cells (MPCs). In the absence of SGCA, FGFR1 is mislocalized to the nucleus, impairing its signaling function and leading to reduced MPC proliferation (Cassano2011Alpha).

The interaction between SGCA and FGFR1 is particularly significant in the context of muscle regeneration and repair, as it facilitates the response to basic fibroblast growth factor (bFGF), a key factor in muscle cell proliferation and survival (Cassano2011Alpha).


## References


[1. (Trabelsi2008Revised) Madiha Trabelsi, Niloufar Kavian, Fatma Daoud, Virginie Commere, Nathalie Deburgrave, Caroline Beugnet, Stephane Llense, Jean Claude Barbot, Aurélie Vasson, Jean Claude Kaplan, France Leturcq, and Jamel Chelly. Revised spectrum of mutations in sarcoglycanopathies. European Journal of Human Genetics, 16(7):793–803, February 2008. URL: http://dx.doi.org/10.1038/ejhg.2008.9, doi:10.1038/ejhg.2008.9. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2008.9)

[2. (Chung2023Novel) Nam Chung Tran, Nguyen Thi Kim Lien, Thanh Dat Ta, Van Hung Nguyen, Huy Thinh Tran, Nguyen Van Tung, Nguyen Thi Xuan, Nguyen Huy Hoang, and Van Khanh Tran. Novel mutations in the sgca gene in unrelated vietnamese patients with limb-girdle muscular dystrophies disease. Frontiers in Genetics, October 2023. URL: http://dx.doi.org/10.3389/fgene.2023.1248338, doi:10.3389/fgene.2023.1248338. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2023.1248338)

[3. (Xie2019Clinical) Zhiying Xie, Yue Hou, Meng Yu, Yilin Liu, Yanbin Fan, Wei Zhang, Zhaoxia Wang, Hui Xiong, and Yun Yuan. Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of chinese patients. Orphanet Journal of Rare Diseases, February 2019. URL: http://dx.doi.org/10.1186/s13023-019-1021-9, doi:10.1186/s13023-019-1021-9. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-019-1021-9)

[4. (Ozawa2005Molecular) Eijiro Ozawa, Yuji Mizuno, Yasuko Hagiwara, Toshikuni Sasaoka, and Mikiharu Yoshida. Molecular and cell biology of the sarcoglycan complex. Muscle &amp; Nerve, 32(5):563–576, October 2005. URL: http://dx.doi.org/10.1002/mus.20349, doi:10.1002/mus.20349. This article has 125 citations.](https://doi.org/10.1002/mus.20349)

[5. (AlonsoPérez2020New) Jorge Alonso-Pérez, Lidia González-Quereda, Luca Bello, Michela Guglieri, Volker Straub, Pia Gallano, Claudio Semplicini, Elena Pegoraro, Vittoria Zangaro, Andrés Nascimento, Carlos Ortez, Giacomo Pietro Comi, Leroy ten Dam, Marianne De Visser, A J van der Kooi, Cristina Garrido, Manuela Santos, Ulrike Schara, Andrea Gangfuß, Nicoline Løkken, Jesper Helbo Storgaard, John Vissing, Benedikt Schoser, Gabriele Dekomien, Bjarne Udd, Johanna Palmio, Adele D’Amico, Luisa Politano, Vincenzo Nigro, Claudio Bruno, Chiara Panicucci, Anna Sarkozy, Omar Abdel-Mannan, Alicia Alonso-Jimenez, Kristl G Claeys, David Gomez-Andrés, Francina Munell, Laura Costa-Comellas, Jana Haberlová, Marie Rohlenová, De Vos Elke, Jan L De Bleecker, Cristina Dominguez-González, Giorgio Tasca, Claudia Weiss, Nicolas Deconinck, Roberto Fernández-Torrón, Adolfo López de Munain, Ana Camacho-Salas, Béla Melegh, Kinga Hadzsiev, Lea Leonardis, Blaz Koritnik, Matteo Garibaldi, Juan Carlos de Leon-Hernández, Edoardo Malfatti, Arturo Fraga-Bau, Isabelle Richard, Isabel Illa, and Jordi Díaz-Manera. New genotype-phenotype correlations in a large european cohort of patients with sarcoglycanopathy. Brain, 143(9):2696–2708, September 2020. URL: http://dx.doi.org/10.1093/brain/awaa228, doi:10.1093/brain/awaa228. This article has 51 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/brain/awaa228)

[6. (Cassano2011Alpha) Marco Cassano, Arianna Dellavalle, Francesco Saverio Tedesco, Mattia Quattrocelli, Stefania Crippa, Flavio Ronzoni, Agnese Salvade, Emanuele Berardi, Yvan Torrente, Giulio Cossu, and Maurilio Sampaolesi. Alpha sarcoglycan is required for fgf-dependent myogenic progenitor cell proliferation in vitro and in vivo. Development, 138(20):4523–4533, October 2011. URL: http://dx.doi.org/10.1242/dev.070706, doi:10.1242/dev.070706. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.070706)

[7. (Mickelson2021Sarcoglycan) James R. Mickelson, Katie M. Minor, Ling T. Guo, Steven G. Friedenberg, Jonah N. Cullen, Amanda Ciavarella, Lydia E. Hambrook, Karen M. Brenner, Sarah E. Helmond, Stanley L. Marks, and G. Diane Shelton. Sarcoglycan a mutation in miniature dachshund dogs causes limb-girdle muscular dystrophy 2d. Skeletal Muscle, January 2021. URL: http://dx.doi.org/10.1186/s13395-020-00257-y, doi:10.1186/s13395-020-00257-y. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13395-020-00257-y)

[8. (Vainzof2021Sarcoglycanopathies:) Mariz Vainzof, Lucas S. Souza, Juliana Gurgel-Giannetti, and Mayana Zatz. Sarcoglycanopathies: an update. Neuromuscular Disorders, 31(10):1021–1027, October 2021. URL: http://dx.doi.org/10.1016/j.nmd.2021.07.014, doi:10.1016/j.nmd.2021.07.014. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.nmd.2021.07.014)

[9. (Kobuke2008A) Kazuhiro Kobuke, Federica Piccolo, Keith W. Garringer, Steven A. Moore, Eileen Sweezer, Baoli Yang, and Kevin P. Campbell. A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice. Human Molecular Genetics, 17(9):1201–1213, February 2008. URL: http://dx.doi.org/10.1093/hmg/ddn009, doi:10.1093/hmg/ddn009. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddn009)